The goal of increasing efficiency, stability, and lowering production costs in photovoltaic (PV) technology has pushed research into a new frontier: the nanoscale. It is now unequivocally established ...

G&A Expenses -- $13.8 million in the fourth quarter, of which $5.6 million was non-cash stock-based compensation; annual G&A ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 Earnings Call Transcript March 12, 2026 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.22551.

The medical courier industry is splitting in two NEW YORK CITY, NY / ACCESS Newswire / March 13, 2026 / On one side, a growing number of technology-enabled providers are using AI dispatch, real-time ...

Introduction Psychedelic-assisted therapy shows promise for treating various mental health conditions; however, its reliance on intensive psychological preparation limits its broader application.